Incyte Reports Positive Phase 3 Results for Tafasitamab Combo in First-Line DLBCL
I'm PortAI, I can summarize articles.
Incyte Corporation reported positive results from the Phase 3 frontMIND trial for tafasitamab (Monjuvi®/Minjuvi®) combined with lenalidomide and R-CHOP as a first-line treatment for newly diagnosed diffuse large B-cell lymphoma (DLBCL). The trial met its primary endpoint of progression-free survival and secondary endpoint of event-free survival, with no new safety concerns. Incyte plans to file a supplemental Biologics License Application for this combination therapy in the first half of 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments